RxAll
PrivateLast Round
Grant
Apr 30, 2025
Total Funding Raised
$4.96M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
RxAll is a health-tech company that provides a digital infrastructure platform for pharmacies and hospitals to authenticate medicines and manage procurement.
Sector
Healthcare & Life Sciences
Verticals
Pharma Supply Chain, Medical Devices, Supply Chain Tracking, Vertical SaaS
Business Model
B2B2C
Customer Profile
Marketplace Commission, Hardware Sales, Subscription SaaS, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RxAll Comparables
Compare RxAll with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Meditect | 79% | |
| Sproxil | 75% | |
| Chekkit Technologies | 75% |
For institutional investors. Book with your work email.
RxAll Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 30, 2025 | ||||
| Series A | Sep 1, 2024 | ||||
| Seed | Jul 20, 2021 | ||||
| Pre Seed | Nov 1, 2020 | ||||
| Accelerator | Sep 21, 2020 | ||||
Grant | Mar 27, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
RxAll Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Equilateral Ventures | Grant |
| Launch Africa Ventures | Pre Seed, Seed |
| LoftyInc Capital Management | Seed |
| Katapult Accelerator | Accelerator |
| Investing in Innovation (i3) Africa | Grant |
| Standard Bank Group | Accelerator |
| Yale University | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
Open roles increased to 9, 2.3x the trailing average.
- Jul 25, 2026
Monthly visitors increased 453% MoM, reaching 4.9K.
For institutional investors. Book with your work email.
RxAll Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RxAll's valuation, stock price, and market status.
Is RxAll a public or private company?
RxAll is a private company.
What is the current stock price of RxAll?
RxAll is a private company, so its shares have no public market price. Caplight tracks RxAll's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RxAll worth (valuation)?
Valuation information for RxAll is not publicly available.
Can I buy RxAll stock?
RxAll shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RxAll's last funding round?
RxAll's most recent funding round was Grant on April 30, 2025.
Who are the main investors in RxAll?
Key investors in RxAll include Launch Africa Ventures, Investing in Innovation (i3) Africa, Founders Factory Africa, SOSV, HAX.
Will RxAll IPO soon?
No public IPO plans have been announced for RxAll.
How can I track RxAll secondary market activity?
Caplight tracks bids, offers, and trades in RxAll's shares on secondary markets.